Recent Updates
Recently added Catalysts

Parkinson's Disease: 5 biotech companies with clinical-stage programmes

Neurology & PsychiatryConcentrated betData as of 2026-09-04

Competitors5in the clinic
Median market cap$1.3Buniverse median $1.20B
Allocated capital$2.5B$8.2B competing
Phase 3 or filed13 mid, 1 early
Pure plays2this indication only
Capital rank79/299crowding rank 37

Parkinson's Disease is a concentrated bet: only 5 US-listed developers are in the clinic, and the median one is worth $1.3B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

1 of the 5 is in Phase 3 or filed, and 5 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$2.5B of allocated capital sits in Parkinson's Disease, 79th of 299 indications, and 2 of the 5 companies are pure plays that trade on this indication alone.

Companies developing drugs for Parkinson's Disease 5

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
PRTAProthenaPrasinezumabPhase 33$503MYes1 31 Dec 2026
DNLIDenali TherapeuticsBIIB122Phase 21$3.6BNo5 31 Dec 2026
BHVNBiohavenBHV-8000Phase 21$2.4BNo7 23 Oct 2026
ACIUAC ImmuneACI-7104.056Phase 23$298MYes1 31 Dec 2026
MGTXMeiraGTx HoldingsAAV-GADPhase 11$1.3BNo2 30 Jun 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile. DNLI holds 45% of the $8.2B competing in this indication.

Why Parkinson's Disease is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Parkinson's Disease has 5 competitors and a median of $1.3B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Narcolepsy Type 11 company · $2.6B · median $7.9BUncontestedChorea1 company · $2.7B · median $16.1BUncontestedObsessive Compulsive Disorder1 company · $2.7B · median $16.1BUncontestedHuntington's Disease2 companies · $2.4B · median $2.8BConcentrated betExcessive Daytime Somnolence1 company · $2.7B · median $10.9BUncontestedSmoking Cessation1 company · $2.7B · median $10.9BUncontestedAlzheimer's Disease5 companies · $2.9B · median $397MOrphan cornerMyotonic Dystrophy Type 13 companies · $2.0B · median $250MOrphan corner

Parkinson's Disease pipeline questions

Which biotech companies are developing drugs for Parkinson's Disease?

Prothena (PRTA, Prasinezumab, Phase 3); Denali Therapeutics (DNLI, BIIB122, Phase 2); Biohaven (BHVN, BHV-8000, Phase 2); AC Immune (ACIU, ACI-7104.056, Phase 2); MeiraGTx Holdings (MGTX, AAV-GAD, Phase 1). Those are the 5 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Parkinson's Disease.

How advanced is the Parkinson's Disease pipeline?

Of the 5 clinical-stage programmes in Parkinson's Disease, 1 is in Phase 3 or filed, 3 are in mid-stage development and 1 is in early-stage development.

How much is the typical Parkinson's Disease biotech company worth?

The median company developing a drug for Parkinson's Disease is worth $1.3B, against a median of $1.20B across the whole universe. $2.5B of allocated capital sits in the indication, ranking it 79th of 299.

When is the next Parkinson's Disease catalyst?

The next dated catalyst in Parkinson's Disease is BHVN on 23 Oct 2026. 5 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map